A Single-center, Open-label, Randomized, Versus a Control Group, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral Lucerastat in Adult Subjects With Fabry Disease Receiving Enzyme Replacement Therapy
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 12 Jul 2017 Results published in the Clinical Pharmacology and Therapeutics
- 21 Jul 2016 Status changed from recruiting to completed, as reported in an Actelion Pharmaceuticals media release.
- 02 Mar 2015 New trial record